Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

SAN FRANCISCO, May 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.

Click to view original post